Log In

    Ocugen, Inc. (OCGN)

    Phase 3 IND Clearance Is Good News We’ve Been Waiting For

    ‌
    Robert LeBoyerMedia Inquiries
    Senior Life Sciences Analyst
    April 9, 2024
    Report ID: 26645
    Get Report
    Refer to the full report for the price target, fundamental analysis, and rating.
    Get Report

    Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

    Already Registered? Click the ‘Get Report’ button to login and view the research report.

    Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

    ‌
    Ocugen, Inc.
    Ticker
    OCGN
    Current Price
    $1.64 0.61%
    Market Cap
    $422.0M
    Price Target
    Refer to Report
    Volume
    2.4M
    52wk Range
    $0.345 - $2.105
    Fundamental Analysis:
    Log in to view
    Rating: Log in to view
    Advanced Market Data
    Related Research Reports
    7/26/2024
    ‌
    Ocugen Completes Phase 1 Dosing For OCU410 In Dry AMD
    Ocugen Completes Phase 1 Dosing For OCU410 In Dry AMD (OCGN)
    0 min read
    5/15/2024
    ‌
    1Q24 Reported With Upcoming Clinical Milestones As Expected
    1Q24 Reported With Upcoming Clinical Milestones As Expected (OCGN)
    3 min read
    4/9/2024
    ‌
    Phase 3 IND Clearance Is Good News We’ve Been Waiting For
    Phase 3 IND Clearance Is Good News We’ve Been Waiting For (OCGN)
    0 min read
    4/3/2024
    ‌
    Progress In Clinical Trials Overshadows FY2023 Filing Delay
    Progress In Clinical Trials Overshadows FY2023 Filing Delay (OCGN)
    0 min read

    Inbox Intel from Channelchek.

    Informed investors make more money. And it’s all about timing. Get it when it happens.

    By clicking submit you are agreeing to the Terms of Use and Privacy Policy
    Log In